Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product sales CAMBRIDGE, MA and DURHAM, ...
Moderna Inc. MRNA announced Wednesday a collaboration agreement with privately held Life Edit Therapeutics Inc. to discover and develop in vivo gene editing therapies. Moderna’s stock edged up 0.4% in ...
- Life Edit's genome editing capabilities to be fully integrated with ElevateBio's other cell and gene enabling technologies, including induced pluripotent stem cells (iPSCs), viral vector, and ...
Novo Nordisk, a health sciences manufacturer, is partnering with Durham’s Life Edit Therapeutics in a deal worth upwards of $1.92 billion. Photo courtesy Novo Nordisk A fast-growing Durham gene ...
DURHAM – Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Life ...
Life Edit Therapeutics Inc., an Elevatebio LLC company, has presented the first preclinical data from the its Huntington’s disease program.
ElevateBio has enjoyed a close look at Life Edit Therapeutics over the past 11 months, with overlaps in the management team and involvement in its portfolio of cell and gene therapy companies giving ...
LONDON, May 24 (Reuters) - Capitalising on strong demand for its obesity therapies, Novo Nordisk's (NOVOb.CO), opens new tab growing appetite for deals has fuelled a bet on a U.S. gene-editing company ...
One of Moderna's New Year's resolutions appears to have been to expand its genomics output. The latest move in this area sees the mRNA company pen a partnership with ElevateBio’s Life Edit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results